This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

About

Efficacy

Safety & Tolerability

Real World Experience

Support & Resources

Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.

Dosing

​​​​​​​An alternative way to treat patient with Psoriatic Arthritis (PsA)1

Tablets shown not true to size.

  • XELJANZ 5 mg can be given with or without food.
  • For patients who have difficulties swallowing, XELJANZ 5 mg tablets may be crushed and taken with water.
  • No dose adjustment is required when used in combination with MTX.
  • Rapid absorption in healthy human subjects with plasma concentrations peaking approximately 1 hour after administration.
  • Terminal half-life of approximately 3 hours.
  • XELJANZ is available in a 28-day treatment pack.
  • XELJANZ contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Packs and tablets shown not true to size.

Contraindications and special populations1

Contraindications for use:

  • Hypersensitivity to the active substance of XELJANZ or to any of its excipients*
  • Active tuberculosis (TB), serious infections such as sepsis, or opportunistic infections
  • Severe hepatic impairment
  • Pregnancy and lactation

Special populations:

​​​​​​​Renal Impairment
  • XELJANZ dose should be reduced to 5 mg once-daily in patients with severe renal impairment (creatinine clearance <30 mL/min).
  • Patients with severe renal impairment should remain on a reduced dose of 5 mg once-daily even after haemodialysis.
Hepatic impairment
  •  XELJANZ dose should be reduced to 5 mg once daily in patients with moderate hepatic impairment (Child Pugh B).
  • XELJANZ should not be used in patients with severe hepatic impairment (Child Pugh C).
Elderly
  • No dose adjustment is required in patients aged ≥65 years based on age alone (see other special populations). There are limited data in patients aged 75 years and older.
  • The elderly population in general has an increased risk of infections; caution should be used when treating the elderly. In patients over 65 years of age XELJANZ should only be considered if no suitable alternative treatment is available.

Drug-drug interactions

  • XELJANZ dose should be reduced to 5 mg once daily in patients receiving potent inhibitors of CYP3A4 (e.g., ketoconazole).
  • XELJANZ dose should also be reduced to 5 mg once daily in patients receiving one or more concomitant medicines that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole).
  • Co-administration of XELJANZ with potent CYP inducers (e.g., rifampicin) may result in a loss of, or reduced, clinical response.
  • Co-administration of potent inducers of CYP3A4 with XELJANZ is not recommended.

Explore more

XELJANZ in Psoriatic Arthritis

In this video, Dr Richard Smith discusses his experience prescribing XELJANZ in PsA.

Watch video

* XELJANZ contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

MTX - methotrexate; TB - tuberculosis; RA - rheumatoid arthritis; PsA - psoriatic arthritis.

Prescribing Information:

XELJANZ (tofacitinib citrate) Prescribing Information -  5mg and 10mg film-coated tablets

​​​​​​​References:
  1. ​​​​​​​​​​​​​​XELJANZ (tofacitinib citrate) Summary of Product Characteristics.
PP-XEL-GBR-2325. June 2021

Announcement Title

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

Dosing in PsA

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No